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Fatty acids are involved in multiple pathways and play a pivotal role in health. Eicosanoids, derived from
arachidonic acid, have received extensive attention in the field of cancer research. Following release from the
phospholipid membrane, arachidonic acid can be metabolized into different classes of eicosanoids through
cyclooxygenases, lipoxygenases, or p450 epoxygenase pathways. Non-steroid anti-inflammatory drugs (NSAIDs) are
widely consumed as analgesics to relieve minor aches and pains, as antipyretics to reduce fever, and as
anti-inflammatory medications. Most NSAIDs are nonselective inhibitors of cyclooxygenases, the rate limiting
enzymes in the formation of prostaglandins. Long term use of some NSAIDs has been linked with reduced
incidence and mortality in many cancers. In this review, we appraise the biological activities of prostanoids and
their cognate receptors in the context of cancer biology. The existing literature supports that these lipid mediators
are involved to a great extent in the occurrence and progression of cancer.Introduction
Dietary fat is an important energy source. Fatty acids that
are produced from catabolism of fats compose an import-
ant aspect of a healthy diet. They are subcategorized into
saturated (lack double bonds) and unsaturated (contain
double bonds) fatty acids. Fatty acids, including polyunsat-
urated fatty acids (PUFA), are usually stored in phospholi-
pids or triglycerides. Essential fatty acids are necessary
polyunsaturated fats that the human body is unable to
synthesize and must obtain through the diet. Two families
with opposing effects belong to this category of fatty acids:
linoleic acid (omega-6) and alpha-linolenic acid (omega-3),
which are the precursors of arachidonic acid (AA) and
eicosapentanoic acid respectively.
In humans, cellular AAs are mainly released from mem-
brane phospholipids by phospholipase A2 and phospholip-
ase C. AAs can also be cleaved from diacylglycerol and is
a minor product of linoleic acid (LA) metabolism. Most
obligate carnivores, however, cannot synthesize AA from
LA and must obtain AA from dietary sources. Arachi-
donic acid can be metabolized through cyclooxygenase* Correspondence: dnie@siumed.edu
1Department of Medical Microbiology, Immunology, and Cell Biology,
Southern Illinois University School of Medicine and Simmons Cancer
Institute, Springfield, IL 62794, USA
2Department of Medical Microbiology and Immunology, Southern Illinois
University School of Medicine, PO Box 19626, Springfield, IL 62794, USA
© 2013 Allaj et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(COX), lipoxygenase (LOX), or epoxygenase mediated
pathways to form a variety of biologically active lipids,
termed as eicosanoids. LOX-derived metabolites include
hydroperoxyeicosatetraenoic acids (HpETE), leukotrienes
(LT), and lipoxins (LX) [1]. The COX pathway produces
prostaglandin (PG) G2 and prostaglandin H2, which is fur-
ther converted into other prostaglandins. The major pros-
tanoids synthesized from COX include prostaglandin E2,
prostaglandin D2, prostacyclin I2, prostaglandin F2a and
thromboxane A2 (TXA2) (Figure 1). Prostanoids are exten-
sively studied for their involvement in a long list of adverse
health conditions, including cancer, inflammation, throm-
bosis, arthritis and atherosclerosis.
Non-steroid anti-inflammatory drugs (NSAIDs) are
widely consumed as analgesics to relieve minor aches and
pains, as antipyretics to reduce fever, and as anti-
inflammatory medications. Most NSAIDs are nonselective
inhibitors of cyclooxygenases (COX), the rate limiting en-
zyme in the formation of prostaglandin H2. Therefore,
NSAIDs can reduce the formation of various prostanoids.
A number of epidemiological studies have linked the long
term use of some NSAIDs, especially aspirin, with reduced
cancer incidence and most significantly, with reduced can-
cer mortality [2-4]. This paper aims to give a brief over-
view of the effect of cyclooxygenases and the prostanoid
signaling in the initiation, progression and treatment of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Biosynthesis and activities of prostaglandins and sites of NSAIDs actions. Cyclooxygenase metabolism of arachidonic acid can
lead to the formation of prostaglandins that exert a variety of biological activities through their respective cognate receptors. The involvement of
prostanoid receptors in cancer is also shown. Abbreviations: COX, cyclooxygenase; PG, prostaglandin; PLA2, phospholipase 2; TXA2, thromboxane
A2; TP, thromboxane A2 receptor; EP, prostaglandin E2 receptor; IP, prostacyclin (PGI2) receptor; DP, prostaglandin D2 receptor; FP, prostaglandin F2
receptor; NSAIDs, non-steroid anti-inflammatory drugs.
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Cyclooxygenases
Currently, three known isoforms of COX exist: COX-1,
COX-2, and COX-3. COX-1 and COX-2, also known as
prostaglandin-endoperoxide synthase 1 and 2 respectively,
catalyze the rate limiting step of prostaglandin synthesis.
COX-1, encoded by the PTGS1 gene, is constitutively
expressed in most mammalian tissues and appears to
regulate normal physiological functions, including the
maintenance of vascular homeostasis, mediation of aller-
gic and immune responses, and stimulation of gastric mu-
cosa production. COX-2, encoded by PTGS2 shares 81%
homology with COX-1, is usually absent from healthy tis-
sue and is transiently induced by pro-inflammatory stim-
uli, growth factors, cytokines, and tumor promoters to
increase the rate of prostaglandin formation after tissue
injury [1]. COX-3 is an alternately spliced variant of
COX-1. Also encoded by the PTGS1 gene, COX-3 proteins
retain an intron and a frame shift mutation, resulting in
non-functional proteins in mice and humans [5].
When an appropriate PUFA binds to the COX active
site, COX catalyzes the oxygenation of the substrate into5-R,6-R’,(1R,4S)-2,3-dioxabicyclo[2.2.1]heptane through a
series of carbon radical intermediates. Both COX-1 and
COX-2 primarily, but not exclusively, oxygenate AAs into
prostaglandin G2s (PGG2)-at least three other minor pro-
ducts exist. PGG2s are then reduced to prostaglandin H2s
(PGH2) by peroxidases. PGH2 is subsequently converted
into biologically functional molecules-including prostaglan-
din E2 (PGE2), which induces fever and stimulates gastric
mucus production, bone re-absorption and uterine contrac-
tions; prostaglandin D2 (PGD2), which mediates vasodilata-
tion, allergic response, and decreases in body temperature;
prostacyclin (PGI2), which potently induces vasodilatation
and inhibits platelet activation; and thromboxane (TXA2),
which functions in contrast to PGI2 and potently induces
vasoconstriction and platelet aggregation (Figure 1).
COX-1 and COX-2 also catalyze the oxygenation of
other PUFAs, including dihomo-γ-linolenic acid (DGLA)
to form the series-1 prostaglandin and thromboxane pre-
cursor PGH1 and series-1 thromboxane TXA1, eicosa-
pentaenoic acid (EPA) to form series-3 prostaglandin
precursor PGH3, and possibly linolenic acids to form
9- and 13-hydroxyoctadecadienoic acids (HODE) [6,7].
The COX enzymes are the primary targets of NSAIDs,
including common over the counter medications such as
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duction of PGs, these drugs suppress the pathways that
mediate inflammation, pain and fever. Long term use of
some of these drugs appears to also offer limited protec-
tion against acute cardiac events, Alzheimer’s disease, and
neoplastic diseases, especially colorectal neoplasms. But
the medications can potentially interfere with the produc-
tion of gastrointestinal mucosa, significantly increasing the
risk of gastrointestinal related side effects, including dys-
pepsia, abdominal pain and occasional perforations. More
recently developed COX-2 specific inhibitors, such as
rofecoxib (Vioxx), are not associated with GI related side
effects, but appear to, along with ibuprofen, significantly
increase the chances of acute myocardial infarction in
already at risk patients-enough of a risk to prompt Merck
to voluntarily withdraw Vioxx from market [1].
Prostanoid signaling
Prostanoids usually act within the tissue, where they are
synthesized, via a carrier-mediated process [8] to activate
the membrane receptors [9-11], or in some cases may
interact with nuclear receptors [12]. The membrane
receptors for prostanoids are termed P receptors, with a
preceding letter indicating the natural prostanoid to
which each receptor is most sensitive, i.e. DP, EP, FP, IP
and TP for PGD2, PGE2, PGF2, PGI, and TXA2, respect-
ively [13,14] (Figure 1). The membrane receptors for
prostanoids are mainly heterotrimeric G protein coupled
receptors (GPCR). Below is a brief overview of GPCRs
for prostanoid signaling.
EP: PGE2 regulates diverse biological processes, includ-
ing cell growth, inflammation, reproduction, sodium
homeostasis and blood pressure [15]. Its biological effects
are complex and often opposing; vasodilation in arterial
and venous systems but constriction of smooth muscle in
the trachea, gastric fundus and ileum [16]. Four EP recep-
tor subtypes (EP1-4) have been cloned and characterized
[17-21]. The mRNAs for all EPs are widely expressed. Al-
though these four receptors uniformly bind PGE2 with
high affinity, when examined on the basis of amino acid
homology, they are not as closely related to each other as
to other prostanoid receptors that use similar signaling
mechanisms [14]. EP2 and EP4 are more closely related to
IP and DP receptors, whereas EP1 and EP3 are more
closely related to TP and FP receptors.
The EP1 was originally described as a smooth-muscle
constrictor. It plays important roles in neuronal func-
tions. The cloned human EP1 receptor cDNA encodes a
402-amino-acid polypeptide that signals via increased
inositol-3-phosphate (IP3) generation and increased
intracellular Ca2+ moblization [17,22].
The human EP2 receptor cDNA encodes a 358-
amino-acid polypeptide that signals through increased
cAMP [21,23]. EP2 receptor plays an important role infemale reproduction, vascular hypertension and tumori-
genesis [24]. The EP2 may also be an important target
for treating asthma by promoting bronchodilation [25].
The EP2 is distinguished from the EP4 by its relative in-
sensitivity to the EP4 agonist PGE1-OH [23]. EP2
mRNA is most abundant in the uterus, lung, and spleen,
with only low levels of expression in the kidney [23,26].
It is expressed at much lower levels than EP4 mRNA in
most tissues [27].
The EP3 receptors generally act as constrictors of
smooth muscle [13]. It is associated with fever, gastric mu-
cosal protection, pain hypersensitivity, kidney function
and anti-allergic response. EP3 has at least nine alterna-
tively spliced variants defined by unique C-terminal cyto-
plasmic tails [28]. These splice variants encode proteins
with predicted molecular masses of between 40 and
45 kDa [23]. The EP3 splice variants bind PGE2, agonists
MB28767 and sulprostone with similar affinities as EP3
[14]. All of the splice variants uniformly and potently in-
hibit cAMP generation via a pertussis toxin-sensitive Gi-
coupled mechanism; however, Ca2+-dependent signaling
mechanisms appear to be differentially activated by differ-
ent C-terminal tails [29-31]. The physiological significance
of these different C-terminal splice variants may play a
role in constitutive regulation of cellular events [32]. The
receptor EP4 signals through increased cAMP [21] and is
a systemic vasodepressor [33].
EP4 directs platelet inhibition at low PGE2 concentra-
tions, but leads to EP3-mediated platelet aggregation at
high concentration of PGE2 [34]. It also has roles in
ductus arteriosus closure and inflammation associated
bone resorption [35]. The human EP4 cDNA encodes a
488-amino-acid polypeptide with a predicted molecular
mass of 53 kDa [21]. EP4 may be pharmacologically dis-
tinguished from the EP1 and EP3 by their insensitivity to
sulprostone and from EP2 by its insensitivity to buta-
prost [26,36].
DP: PGD2 is the major COX product released by mast
cells during allergic responses. It has been associated with
the development of pulmonary inflammatory diseases
such as asthma [37]. PGD2 also plays a role in regulating
sleep-wake cycles [38] and pain perception [39]. Two
receptors for PGD2, DP1 [40] and DP2 [41], have been
cloned from human cells. DP1 is coupled positively to
adenylyl cyclase though Gs [14] and this results in strong
inhibitory effects on platelet aggregation, bronchodilation
and vasodilation in humans [42,43]. DP2 (also known as
CRTH2) is preferentially expressed in T-helper type 2
cells, eosinophils, and basophils. Activation of DP2 leads
to mobilization of intracellular Ca2+. DP2 also directs
PGD2-induced chemotaxis and migration of TH2 cells
[44]. Both DP1 and DP2 integrate coordinately the effects
of PGD2 on eosinophils, modulating chemokinesis, de-
granulation, and apoptosis [45].
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PGH2 via a PGF synthase or from PGE2 via a 9-keto re-
ductase. PGF2α is the trigger that initiates luteolysis or
regression of the corpus luteum in the absence of preg-
nancy [46]. It is also a contractor of smooth muscle
across a variety of tissues [47]. PGF2α induces cardiac
myocyte hypertrophy and induction of myofibrillar gene
[48]. Thus far, one membrane receptor for PGF2α (FP) in
human cells has been cloned [49]. Stimulation of FP
activates Rho kinase, leading to the formation of actin
stress fibers, phosphorylation of p125 focal adhesion kin-
ase, and cell rounding [50]. FP is highly expressed in
skin, where it may play an important role in carcinogen-
esis [51]. FP also appears to have an important role in
the eye, where it increases uveoscleral outflow and
reduces ocular pressure [52].
IP: Prostacyclin (PGI2) was first discovered in 1976 as
an unstable eicosanoid in blood vessels [53]. It is very la-
bile and undergoes spontaneous transformation to 6-
keto-PGF1α within minutes in vivo [54]. Prostacyclin is a
potent endogenous anticoagulator for platelets and a
strong vasodilator [53]. It is the most abundant product
of arachidonic acid in vascular tissues [55]. Like many
other lipid mediators of the eicosanoid family derived
from arachidonic acid, PGI2 is produced by the COX
system. PGI2 synthase (PGIS) converts PGH2 to PGI2
[56]. On-site production of PGI2 is executed by either
COX-1 or COX-2 coupled to PGIS [57]. However, PGI2
is a primary product of COX-2 in certain systems [58-60].
Prostacyclin signaling pathway involves both cell surface
and nuclear receptors [61]. However, the classical signal-
ing pathway of PGI2 is to use a G protein coupled receptor
termed IP [62]. IP mRNA is abundantly expressed in kid-
ney, liver, heart and lung [63]. Activation of IP by PGI2
leads to an increase in cAMP and activates protein kinase
A cascade, or calcium mobilization via phospholipase
C activation [64].
TP: Thrombosane A2 (TxA2) is produced from PGH2
by TX synthase. It is a modulator of platelet shape
change and aggregation. TxA2 is a potent vasocon-
strictor, mitogen and platelet activator [65-67]. TxA2
may also mediate cellular hypertrophy [68]. The human
TxA2 receptor (TP) was the first eicosanoid receptor
cloned in 1991 [69]. Two alternatively spliced variants of
human TP have been described [70]. These variants dif-
fer in the C-terminal tail of the receptor distal to Arg-
328. The original placenta-derived clone of 343 amino
acid residues receptor has been designated as TPα, and a
407 residue splice variant cloned from endothelium is
designated as TPβ. TP mRNAs are expressed widely in
the lung, liver, kidney, heart, uterus, and vascular cells
with TPα as the dominant isoform [71]. Both TPα and
TPβ couple via Gq, G11, and G12/13 to activate PLC-
dependent inositol phosphate generation and elevateintracellular calcium [63]. Activation of TP by TxA2, or
by more stable synthetic agonists, evokes the activation
of phospholipase C and a subsequent rise in the intracel-
lular calcium ion concentration, leading to vasoconstric-
tion and platelet aggregation [72,73]. It is interesting to
note that TPα and TPβ appear to dimerize, and their
coexpression augments iPF2α-III (an isoprostane) signal-
ing when compared to either receptor alone [74].
Cyclooxygenases and cancer
Speculation of COX enzymes’ involvement in carcino-
genesis and progression existed since 1976. That year, a
small study showed that the osteolytic activities of 8 out
of 9 osteolytically active tumors excised from patients
with breast cancer were significantly inhibited by aspirin,
a nonselective COX inhibitor [75]. Since then, aberrant
over-expression of COX has been consistently associated
with malignant transformation of healthy tissue, prolif-
eration and increased invasiveness of malignant tissue,
and unfavorable clinical outcomes. Up-regulations of
COX enzymes have been reported in many human can-
cers and accumulation of PGE2, PGF2α (a PGE2 deriva-
tive), and PGI2 are features of many epithelial cancers.
COX-1 is up-regulated in cervical, ovarian and gallblad-
der cancers [1]. COX-2, which is normally undetectable
in healthy tissue, is markedly over-expressed in colorec-
tal, lung [76], prostate [77], cervical [78], ovarian [79],
breast, gastric, pancreatic [80] and certain head and neck
squamous cell [81] cancers. In the following paragraphs,
we will examine the involvements of COXs in tumor ini-
tiation and progression in more depth.
Cyclooxygenase involvement in tumor initiation
Studies in the laboratory are establishing COX enzymes’
roles in cancer initiation. Aberrant COX expression alone
is not known to initiate tumors, but significant up-
regulation of these enzymes is frequently associated with
premalignant alterations in epithelial tissues. In addition
to causing chronic inflammation, immunological studies
have shown that COX products, especially Prostaglandin
E2, interfere with the antitumor activities of the immune
system. PGE2 inhibits T lymphocytes from producing anti-
tumor TH1 cytokines and inhibit the antitumor functions
of natural killer cells and macrophages [1]. Also, in tissues
with low cytochrome P450 expressions, COX enzymes
oxidize a significant amount of xenobiotics into mutagens
and generate mutagens as by-products during prostaglan-
din synthesis [1]. Those endogenously produced mutagens
can cause DNA damages as tumor initiators.
In vivo experiments have shown that APCMin mice
lacking COX-2 develop 80% fewer intestinal neoplasias
than mice that express wild type COX-2 [82], and these
COX-2 deficient mice also develop 75% fewer papillo-
mas than wild-type mice in a multistep tumor initiation/
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this correlation between COX-2 over-expression and
premalignant and malignant lesions in epithelial tissues.
Both pharmacological inhibition of COX-2 using cele-
coxib, a selective COX-2 inhibitor, and genetic knockout
of COX-2 protected mice from UV-induced nonmela-
noma skin cancers [84]. Mice that over-express COX-2 in
basal epidermal cells, through keratin 5 promoters, are
significantly more susceptible to genotoxic carcinogens
than wild-type mice, and develop epidermal hyperplasia
and dysplasia after single epicutaneous applications of
0.5 μM DMBA in 0.1 ml acetone [85].
Although there is strong evidence suggesting COX-2’s
involvement in tumor initiation, COX-1’s functional role
in carcinogenesis remains unclear – these same mice
models have produced inconsistent data. While COX-1
deficient APCMin mice also presented with an 80% lower
incidence of intestinal neoplasia [82], COX-1 deficiency
offered no protection against skin cancers in the UV-
induced carcinoma model [84]. The studies suggest a po-
tential role for aberrant expression and activities of COX-
2, but less likely COX-1, in initiating tumor formation.
Cyclooxygenase involvement in tumor growth
and progression
Further studies have identified the COX enzymes as im-
portant components for tumor growth, survival and pro-
gression. Clinical surveys have found an average of a 3.3
fold difference between the expression of COX-2
enzymes in malignant prostate cancer tissues and in-
flammatory benign prostate hyperplasia tissues [77]. The
same study also found marked increases of Bcl-2, an
apoptosis suppressor, and vascular endothelial growth
factor (VEGF), an angiogenesis modulator linked to
accelerated tumor progression and increased invasive-
ness, in malignant prostate tissues [77]. In vitro studies
have confirmed the correlation between COX-2 and
many of these observations. Treatment with PGE2 recep-
tor (EP) antagonists and siRNA silencing of COX-2 in
Hela cervical cancer cell coincides with sharp decreases
in VEGF-C protein and mRNA expression respectively
[86]. Stromal fibroblasts isolated from COX-2 deficient,
but not COX-1 deficient, mice also produces far less
(>90%) VEGF than fibroblasts from wild-type mice [87].
Therefore, COX-2 appears to not only mediate tumor
growth, but also it can elicit other changes from host tis-
sues, such as neovascularization, to support tumor
growth and progression.
Animal model experiments have echoed these find-
ings. Although not statistically significant when com-
pared to control groups, 25 mg/kg of body weight dose
of celecoxib administered daily via gavage feeding tubes
inhibited the growth of subcutaneously implanted
SKOV-3 human ovarian carcinoma cells by 15% over28 days in nude mice. Co-administration of celecoxib
and 3 mg/kg SC-560, a selective COX-1 inhibitor, inhib-
ited tumor growth by a statistically significant 36% over
the same period of time [88]. Immunohistochemistry
revealed significantly lower KI-67 expression in the
tumors excised from all three (SC-560, celecoxib, and
SC-560/celecoxib) treatment groups than the tumors
from the control group [88]. TUNEL assays detected sig-
nificant increases in fragmented DNA in the SC-560 or
celecoxib treated groups, and a 167% increase, over the
control group, in the SC-570/celecoxib group [88].
Another study confirmed that pharmacological inhib-
ition of COX-2, but not COX-1, dramatically reduces
cellular proliferation in vitro. Treatment of BxPC-3 cells,
a COX-2 positive pancreatic adenocarcinoma cell line,
with 25 μM or 50 μM NS-398, a selective COX-2 inhibi-
tor, inhibited cell growth by 30% and 50% respectively
[89]. Further, this study established a link between COX-
2 expression and angiogenesis, the formation of new
blood vessels that is required for tumor growth beyond
2-3 mm [1]. Pretreatment of BxPC-3 cells with 50 μM
NS-398 inhibited BxPC-3 induced Bovine Aortic Endo-
thelial Cell migration, a crucial step of the angiogenic
process, by 68%; while treatment with 5 μM PGE2 after
50 μM NS-398 partially restored BAEC migration. Fur-
ther, endothelial cells seeded onto Matrigels and co-
cultured with BxPC-3 cells differentiated and developed
into tube like structures in vitro, a phenomenon that is
not observed in control groups lacking cancer cells or
experimental groups that are continuously exposed to
50 μM NS-398. Mouse Matrigel plug assay, an in vivo
angiogenesis model, further confirmed the angiogenesis
inducing potential of COX-2 products. Mice injected
with culture medium derived from BxPC-3 cells pre-
sented a 10 fold increase, over the control group, in neo-
vascularization; versus only a 2.9 fold increase in mice
injected with culture medium derived from AsPC-1, a
COX-2 negative cell line. Furthermore, pretreatment of
BxPC-3 cells with 50 μM NS-398 completely abrogated
the derived culture medium’s ability to stimulate neovas-
cularization in these mice [89].
There are numerous other studies in support of the
anti-cancer activities of COX-2 inhibitors, most notably
celecoxib. However, it should be noted that not all anti-
cancer activities of celecoxib or other NSAIDs can be con-
tributed to inhibition of COX activities and reduction of
prostanoid biosynthesis. In fact, for example, the induction
of apoptosis of celecoxib has been found not associated
with inhibition of COX-2 [90]. As a small molecule, cele-
coxib can have off target activities, as evidenced by the
observations that the acute cytotoxicity of celecoxib can
be separated from its inhibition of COX-2. In addition to
celecoxib, other NSAIDs can exert anti-proliferative or
cytotoxic effects through various COX-independent
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regarding various off target effects of NSAIDs including
COX-2 selective inhibitors.
Cyclooxygenase involvement in tumor invasion
and metastasis
Given the involvement of COX-2 in cancer development
and progression, clinical surveys have, not surprisingly,
found strong positive correlations between high COX-2
expression and unfavorable clinical outcomes, especially
metastasis [79]. The risk of death for patients with
COX-2 positive ovarian cancer is 2.8 times that of the
patients with COX-2 negative ovarian cancer – COX-2
expression, in this case, is a more predictive prognosis
indicator than FIGO stage or histological grade [79].
COX-2 has been shown to promote invasive phenotypes
through increased expression of matrix metalloproteinases
(MMP) 1 and 2 to break down the extracellular matrix
and decrease cell-cell adhesion, in human colon cancer
cells and the hyaluronate receptor CD44, glycoprotein
receptors involved in cell adhesion and migration, in colon
[80] and non small-cell lung [1] cancers. Other studies
have also confirmed that there is significantly higher
COX-2 and VEGF-C expressions in lymph node metasta-
sis (LNM) positive than in LNM negative cervical and
lung cancers specimens [86]. Experiments have shown
that in vitro siRNA knock-down of VEGF-C in A548 lung
cancer cells partially restored epithelial phenotype, signifi-
cantly decreased specific mesenchymal markers, and dras-
tically decreased the side population of cells expressing
cancer stem cell markers [92], which are speculated to
contribute to the invasiveness and chemo- and radio-
resistance in tumors [93]. Pharmacological inhibition of
COX enzymes by NSAIDs has been shown to lower serum
VEGF-C levels in patients. Celecoxib, when orally admi-
nistered, lowers VEGF serum levels by as much as
15%-25% [94]. Orally administered 50 mg/kg rofecoxib,
another selective COX-2 inhibitor, predictably decreased
the incidence of liver metastasis in BALB/c mice carrying
implanted MC-26 murine colon cancer cells in their
splenic subcapsule. These treated mice also had a far lower
mortality rate than the control group, 10% versus 90%
after 30 days [95]. The studies generally support the ra-
tionale of using COX-2 inhibitor to reduce tumor invasion
and metastasis. However, due to the adverse effects of long
term use of COX-2 inhibitors, it is still unclear whether
there is a therapeutic window of using COX-2 inhibitors
in reducing tumor invasion and metastasis in a safe and
effective way.
Among the downstream of COX, PGE synthase is ex-
tensively studied for its potential role in tumor progres-
sion and already subjected to a number of reviews
[96-100]. Evidence accumulates suggesting another down-
stream enzyme, thromboxane (TX) synthase in tumorprogression. TX synthase converts PGG2 to TXA2.
Astrocytoma cells selected for migratory ability revealed
that enhanced motility is coincided with up-regulated
expression of a TX synthase homolog [80]. Increased ex-
pression of TX synthase was found in prostate cancer
specimens with advanced stage and perineural invasion
[101]. Further in vitro experiments have confirmed that
up-regulation of TX synthase increases the migratory
ability of DU-145 cells, a moderately invasive prostate
cancer cell line, and SQ-29548, a potent and selective
TXA2 receptor antagonist, interferes with the migratory
ability of these cells [101]. NS-398 inhibited TXA2 syn-
thesis in vitro by roughly 80%, and combination treat-
ment with piroxicam, a selective COX-1 inhibitor, and
NS-398 reduced TXA2 synthesis by 95% [101]. There-
fore, in cancer cells, both COX isoforms can contribute
PGH2 to form TXA2. Further studies of enzymes down-
stream of COX may provide target of intervention to re-
duce tumor invasion and metastasis as results of aberrant
COX-2 or COX-1 expression and activities.
Prostanoid receptors and cancer
There is even evidence of COX product dependence in
malignant tissues that do not exhibit aberrant endogen-
ous COX expressions. One study showed that COX-
deficient pancreatic cancer cell lines AsPC1 and Mia-
PaCa2 undergo significant increases in cell proliferation
after treatment with concentrations of PGE2 as low as
1 μM; and these cells showed markedly slowed growth
after siRNA knockdown of MRP4, the main prostaglan-
din transporter [102]. This suggests that prostanoids are
essential to cancer progression, and abnormally high
concentrations of prostanoids, such as PGE2, in the cel-
lular microenvironment, produced by non- or premalig-
nant tissues that over-express COX enzymes, may affect
cancer progression and clinical outcomes just as much
as endogenous COX over-expression.
The receptors for prostanoids are involved in many
pathophysiological processes, and they have been often
linked to various diseases such as inflammation, athero-
sclerosis and cancer. For instance, it has been shown
that prostaglandin E2 induced activation of EP4 mediates
RCC7 cell invasion [103]. Specifically, EP4 that is
expressed in renal cancer cells initiates a variety of sig-
naling cascades that are transduced by activated Gαs.
This signal transduction pathway further encompasses
production of the second messenger cAMP by adenylyl
cyclase and subsequent activation of Rap signaling that
promotes cell migration [103].
Another study examined the role of EP receptors in
invasiveness of breast cancer cells of murine (C3L5) and
human (MDA-MB-231 and MCF-7) origin [104]. The
major finding of this study was that breast cancer cells
with high metastatic potential (C3L5 and MDA-MB-231)
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noninvasive MCF7 cell line [104]. Moreover, the mRNA
profiles for EP receptors were evaluated. It was observed
that human cell lines expressed all four receptors but the
murine cell line lacked expression of EP2 receptor. EP4
induced activation of the effector molecule PKA was
implicated in an autocrine PGE2 migratory activity. Inter-
estingly, the basal migration index of MCF7 (1.3+/−0.4%)
cells was lower than those of MDA-MB-231 (28.1+/−6.4%),
proving dissimilar migratory abilities [104].
These results are in close agreement with the implica-
tion of the EP1 signaling pathway in the local invasive-
ness and metastasis of oral squamous cell carcinoma
[105]. This study provided evidence that PGE2 increases
cell motility by activation of EP1, PKCδ, c-Src, c-Jun,
and AP-1 signal cascade [105]. The transcriptional activ-
ity of c-Jun leads to expression of ICAM-1 that mediates
adhesion-dependent cell-to-cell interactions and is
known to facilitate movement [105].
Interestingly, another study demonstrated that
decreased expression of EP1 at RNA level correlated
with a poor prognosis in breast cancer patients [106].
Microarray analysis data suggest that the majority of
tumors from European American women (72%) that
showed significant levels of EP1 mRNA were correlated
with a higher survival rate than African American
women who expressed very low levels of EP1 mRNA
[106]. Nuclear localization of EP1 had a beneficial im-
pact on survival [106].
Evidence suggests that EP2 mediated signaling plays a
pivotal role in the proliferation and apoptosis of human
hepatoma cell lines (HepG2 and SMMC-7721) [107].
Results indicated that expression of EP2 directly correlated
with elevated expression of the anti-apoptotic protein Bcl-2
[107]. In contrast, paeoniflorin induced apoptosis in liver
cancer cells by suppressing expression of EP2 and aug-
menting Bax and cleaved caspase-3 levels [107].
Furthermore, the biological capability of prostaglandin
E2 to induce EP4 activation and metastasis of breast can-
cer cells involves a mechanism that requires natural killer
cells [108]. NK cells have been demonstrated to express all
four EP receptors, but preferential activation of EP4 by
PGE2 is responsible for inhibition of NK cell migration
and cytokine secretion [108]. The compromised function
of NK cells contributes to suppression of critical NK cell
functions involved in control of metastasis [108].
Recent studies have demonstrated that PGD2 coupling
to DP receptor promotes inhibitory effects on NK cell
functions [109]. The considerable clinical implication in
cancer derives from the fact that DP is expressed on
human NK cells and PGD2 mediated activation of this
receptor leads to inhibition of the cytotoxic and chemo-
tactic effects as well as decreased accumulation of type 1
cytokine. Intriguingly, this inhibition prevents NK cellmigration toward the inflammatory site [109]. A low
dose (10nM) of PGD2 is sufficient to inhibit NK func-
tions. This anti-inflammatory response may prove to be
beneficial in cancer treatment [109]. The therapeutic po-
tential of DP agonists has also been demonstrated by the
fact that DP deficiency enhances tumor progression and
angiogenesis [110]. Specifically, DP expression in endo-
thelial cells decelerates vascular leakage which results in
decreased tumor angiogenesis and tumor growth [110].
Further, it has been speculated that both aldo-keto re-
ductase AKR1C2 and AKR1C3 mediated PGD2 catabol-
ism enhanced prostate cancer cell proliferation via FP
and PI3K/Akt signaling pathways [111].
Studies have highlighted the mechanism of FP recep-
tor signaling in alteration of epithelial cell invasion and
endothelial cell function in endometrial cancer [112].
Ligand (PGF2a) induced activation of FP in the epithelial
cells of endometrial adenocarcinoma, results in stimula-
tion of the calmodulin-NFAT signaling pathway [112].
This signaling cascade leads to elevated ADAMTS1
which functions in an autocrine/paracrine manner to
promote epithelial cell invasion via ECM and a paracrine
manner to inhibit endothelial cell proliferation [112].
The same group also suggested the presence of a posi-
tive feedback loop that regulates neoplastic epithelial cell
function in endometrial adenocarcinoma [88]. Specific-
ally, COX-2 induced production of PGF2a stimulates its
binding to the FP receptor and subsequent Gq and 1,4,5-
triphosphate activation [88]. The later results in stimula-
tion of ERK signaling and subsequent enhanced produc-
tion of fibroblast growth factor 2 (FGF2) and expression
of additional COX2. FGF2 association with FGFR1 pro-
motes phosphorylation of ERK and enhanced cellular
proliferation [88].
Further, it has been proposed that PGF2a – FP associ-
ation potentiates angiogenesis in endometrial adenocar-
cinoma through activation of EGFR and subsequent
ERK1/2 signaling. This resulted in enhanced signaling
and transcription of the vascular endothelial growth fac-
tor (VEGF) [113].
Expression of the prostacyclin receptor IP is indicative
of the angiogenic phenotype of tumor endothelial cells
according to findings that suggested that migration and
tube formation of TEC were inhibited by the IP receptor
antagonist RO1138452 [102]. According to the same
study, IP receptor is required for induction of angiogen-
esis. It has been speculated that stable prostacyclin ana-
logues reduce lung and lymph node metastasis in
mammary carcinoma models [114].
It has been reported that thromboxane A2 receptors
(TXA2R, or TP) play a pivotal role in cell transformation
and proliferation of neoplastic human lung cells through
expression of Nurr1 [115]. Nurr1 an orphan nuclear re-
ceptor has been identified as the downstream effector of
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and stimulation of Nurr1 expression was mediated via
the PKA/CREB, PKC and ERK signaling pathways in
H157 cells [115]. Nurr1 is believed to mediate cyclin D1
expression and cell proliferation. Moreover, constitutive
interaction between TPα/TPβ and PRK1 leads to phos-
phorylation of histone H3 at Thr [11] and associated cell
migration and proliferation in prostate carcinoma cell
lines [116]. It has been noted that TPβ could be used as
a predictor of prognosis for bladder cancer, since bladder
cancer cell lines express this isoform unlike SV-HUC
that exclusively express TPα [117]. TPβ expression posi-
tively correlates with cell proliferation, migration and in-
vasion in bladder cancer [117]. In prostate cancer,
activation of TP could lead to cytoskeletal reorganization
and rapid cell contraction through activation of small
GTPase RhoA [118]. Blockade of TP activation compro-
mised tumor cell motility [118].
Despite the above described studies indicating the in-
volvement of prostanoid receptors in cancer (Figure 1),
it still remains to be defined when and how prostanoid
receptors are enlisted during tumor formation and pro-
gression, and whether prostanoid receptors can be a tar-
get of intervention for cancer prevention and treatment.
Targeting cyclooxygenases for cancer prevention
and treatment using NSAIDs
Experiments in the laboratory have indicated that COX
inhibitors are promising candidates that could be used
to treat cancer. So far, COX inhibitors have been shown
not only to inhibit tumor initiation and accelerated pro-
gression, but also to preferentially affect cancer cells. At
least one study has reported that in vitro 100 μM NS-
398 treatments markedly reduced the viability of LNCaP,
an androgen-sensitive human prostate adenocarcinoma
cell line, but not the viability of human fetal prostate
fibroblasts. Analysis of the genomic DNA extracted from
these cells also showed that only malignant cells experi-
enced increases in DNA fragmentation, 11 folds to be
precise, after three days treatment [119].
These findings, however, have not been translated suc-
cessfully into the clinics. Initial findings show that COX
inhibitors are ineffective at preventing polyp growth in
patients with familial adenomatous polyposis coli (FAP)
at the anti-inflammatory doses, but long term use of
these drugs at higher doses are associated with serious
side effects. Nonselective COX inhibitors are often asso-
ciated with gastrointestinal problems, including serious,
albeit rare, gastric and duodenal perforations, and select-
ive COX-2 inhibitors are associated with significantly
increased risk of acute myocardial infarctions in already
at-risk patients [1], although more recent studies show
that celecoxib can be safely administered at 800 mg/day
in combination with other treatments [120].So far, clinical trials involving treatment regiments that
target the COX pathway have produced mixed results.
While, low dose celecoxib used in combination with
temozolomide, a DNA methylation/alkylation agent
often used to treat glioblastoma multiforme and melano-
mas after gross surgical resection and radiotherapy, does
prolong progression free survival for patients with glio-
blastoma multiforme, it also, rather counter-intuitively,
increases the likelihood of distant metastases by 3 to 12
folds [121]. Orally administered 400 mg celecoxib twice
a day decreased the KI-67 index in bronchi tissues
extracted from former smokers by an average of 34%
over six month, compared to only 3.8% in the placebo
group [122], while the same dose taken in combination
with palliative chemotherapy for patients with non-small
cell lung cancer (NSCLC) provided no survival benefit
over the placebo [123]. Patients who take selective COX-
2 inhibitors for one year or more are at a lower risk for
colorectal cancers, but at a significantly higher risk for
breast and hematological cancers [124]. These mixed
results make it necessary to further elucidate the mech-
anism of actions of NSAIDs in reducing cancer inci-
dence and/or mortality so that a subset of patients can
be identified for targeted use of NSAIDs for cancer pre-
vention or treatment.
Targeting the prostanoid signaling pathways for
cancer treatment
Long-term administration of patients with COX-2 se-
lective inhibitors may have consequences such as severe
cardiovascular complications. Due to this major draw-
back of the current therapeutic strategies aiming at in-
hibition of cyclooxygenase activity, efforts are currently
underway to discover administration of prostanoid sig-
naling pathway antagonists.
Prostacyclin (PGI2) is the main product of arachidonate
metabolism and has pleiotropic biological activities such
as vasodilation. Its role as an endogenous inhibitor of
platelet aggregation has been further investigated as a
beneficial activity to reduce tumor metastatic process
[125]. Specifically, a study indicated that lungs treated with
PGI2 had 40–50 times fewer metastatic nodes when com-
pared to the positive control [126]. The same study
showed that treatment of mice with PGI2, resulted in a
10% decrease of metastatic cell adhesion to the endothelial
tubules [126]. An alternative approach for the therapeutic
targeting of prostanoid signaling, was the examination of
the inhibitory effect of COX selective inhibitors on prosta-
cyclin. A significant inhibition of prostacyclin synthase ac-
tivity was observed in human endothelial cells, following
treatment with rofecoxib [127]. Currently a plethora of
prostacyclin receptor (IP receptor) agonists such as ilo-
prost, cicaprost and carbacyclin have been reported. How-
ever, only a few highly selective IP receptor antagonists
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lamino]-3-phenyl-propionic acid are known [128]. It still
remains to be elucidated when and how PGI2 and its re-
ceptor can be exploited for cancer treatment.
Reports regarding the major COX-2 metabolite PGE2
and its association with the development of colorectal
cancer and other malignancies through its cognate
receptors have been extensively published. Experimental
evidence supports that ONO-8711, an E-prostanoid re-
ceptor antagonist, inhibits PGE2 signaling without any
interference on the PGF2a production or PGIS expres-
sion [129]. The fact that it has no effect on prostacyclin
production might render ONO-8711 as a safer chemo-
preventive agent regarding cardiovascular events [129].
Another study showed that indomethacin, a major
NSAID, antagonizes human EP2 receptors. The unfavor-
able lack of efficacy and specificity of indomethacin led
to the consideration of other therapeutic agents [130].
Epigallocatechin-3-gallate, a naturally occurring dietary
compound extracted from green tea has been identified
as a potent suppressor of cellular PGE2 biosynthesis
[131]. The same substance has been shown to synergis-
tically augment celecoxib-mediated suppression of PGE2
as well as decrease the amount of the COX-2 inhibitor
(celecoxib) necessary for the production of the anti-
tumoral effect [132].
Another eicosanod studied as a target for cancer preven-
tion and treatment is the thromboxane A2 formed by the
action of thromboxane A2 synthase (TXA2S). An ap-
proach that has been investigated is the inhibition of
TXA2S, which involves selective suppression of thromb-
oxane formation. Dazoxiben is an example of this class of
drugs and prevents the conversion of PGH2 to TXA2. This
drug shifts the direction of metabolism towards the pro-
duction of PGI2 and PGD2 [133]. Researchers tested the
effects of administration of pirmagrel, a thromboxane
synthetase inhibitor in 10 renal allograft recipients with
cyclosporine nephrotoxicity and found that it effectively
suppresses the production of TXA2 as indicated by the re-
duction in the levels of the inactive TXB2 (96% mean sup-
pression) and other thromboxane derived metabolites
[134]. These results are in close agreement with decreased
levels of TXB2 in serum during UK-37 248 TXA2S inhibi-
tor administration. In addition, the imidazole derivative
UK 37 248 increased the production of PGE2 and PGF2a
[135]. Another TXA2 synthase inhibitor OKY046 inhibits
not only the production of TXA2 but also its release with-
out increasing PGI2 synthesis [136]. Remarkably, E3040, a
dual inhibitor of 5-lipoxygenase and thromboxane syn-
thase at 30 and 100 mg/kg inhibited the synthesis of leu-
kotriene B4 and thromboxane B2 but increased the
production of PGE2 [137].
Further strategies have focused upon the direct block-
ade of the TP receptor. SQ29548 is a standard TPantagonist that has contributed to the investigation of
TP mediated processes. Several data have indicated that
domitroban (S-1452/S-145) which is a TP antagonist, is
more potent than OKY046 (TXA2S inhibitor) and is cap-
able of hampering cytokine synthesis [138]. Ramatoro-
ban (Bay U3405) is a potent long lasting inhibitor of
U46619 (TXA2 agonist). Research has shown that it is
effective after either intravenous or oral administration
in male Dunkin Hartley guinea pigs with ID50 values of
600 ug/kg and 1.7 mg/kg respectively [139]. Extensive
studies have shown that combined administration of as-
pirin with TP antagonist apigenin, essentially potentiates
the inhibitory effect on the cyclooxygenase TXA2 path-
way in the instance of aspirin failure to properly sup-
press the TXA2 pathway [140]. Other flavonoids such as
genistein and luteolin have been shown to displace bind-
ing of radiolabeled SQ29548 by >50% to different cell
types [141]. Several lines of evidence suggest that a su-
perior method for the reduction of TXA2 synthesis is
the development of drugs that have dual functions as TP
antagonists and thromboxane synthase inhibitors. The
category of dual acting drugs includes: picotamide
(G137), samixogrel (DTTX30) and BM-531 [142].
Most inhibitors of prostanoid signaling are developed
for cardiovascular indications or as anti-inflammatory
agents. Clearly more studies are needed to define the
involvements of prostanoids in tumor formation and
progression and to evaluate the utility of these proosta-
noid inhibitors in cancer prevention and treatment.Conclusion and perspective
COX enzymes clearly become deregulated in cancers
and all research indicate that these metabolic pathways
are involved in carcinogenesis and tumor progression.
Studies using animal models have demonstrated that
these enzymes are promising targets for intervention;
in vivo models consistently show that COX inhibitors in-
hibit tumor incidence, growth, and acquisition of inva-
sive phenotypes. Unfortunately, these results have not
yet been translated into the clinics successfully.
COX expression is indicative of poorer prognosis for
cancer patients, but the biological effects of its metabo-
lites are diverse and often in opposition. Most studies in-
dicate that the ultimate fate and biological effect of
PGH2 is largely tissue dependent, blind systemic inhib-
ition of COX enzymes risks upsetting the delicate COX
metabolite homeostasis, so it’s not surprising that clin-
ical trials have produced largely inconsistent results.
Groups, however, have independently confirmed that se-
lective inhibition or deletion of specific PGE2, PGF2α,
TXA2 receptors produces many of the same effects as
direct COX inhibition [143-146]. Further research
into these specific downstream pathways should be
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likely to yield desirable results.
There is no complete account of how COX and LOX
enzymes become deregulated in cancer. Even though the
demand for this answer might be considered unreason-
able, especially since many other unknowns that are far
more likely to yield immediate therapeutic options still
exist. This question, however, is scientifically intriguing
and an answer is necessary for a holistic understanding
of cancer biology. Studies have already reported that co-
administration of COX and LOX inhibitors produces a
synergistic effect. More recently, studies have reported
that NSAID induced apoptosis coincides with increased
15-LOX expression and activity [147,148] and that cele-
coxib treatment may affect LTB4 levels in lung, colon
and prostate cancers [149,150] So far, evidence only hint
that these pathways are connected or operate in concert.
More research should be conducted to clarify this
connection.
Finally, LOX isozymes oxygenate a diverse set of
PUFAs, not just AA. Metabolites generated from other
substrates often exert effects that oppose those of the
AA metabolites. Studies have found correlations between
dietary ω-6 fatty acids and cancer [151], and at least one
study has reported that dietary ω-3 fatty acid supple-
ments enhance anti-VEGF and COX inhibitor thearpies
[152]. Research into this field can have profound impact
on our understanding of nutrition and identify diets that
supplement and enhance existing treatments.
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